Exomind and TMS

Key Takeaways

What is TMS? Transcranial magnetic stimulation (TMS) is a non-invasive brain-stimulation technique. A magnetic coil is positioned near the head and produces rapidly changing magnetic fields. These fields induce weak electrical currents in targeted brain tissue, allowing clinicians to influence the excitability and activity of selected neural circuits. TMS does not require an electrode or surgical implant to be placed inside the brain.[3][4]

What does rTMS mean? Repetitive TMS (rTMS) means that magnetic pulses are delivered repeatedly according to a defined protocol. Frequency, intensity, number of pulses, target and timing can all vary. That is why the word 'TMS' alone does not describe one universal treatment.[3][5][6]

What is TMS used for? rTMS has established clinical uses for selected mental-health conditions. NIMH describes rTMS as an FDA-authorized brain-stimulation therapy for specific indications including depression and OCD, while newer applications continue to be studied. The exact regulatory indication depends on the device and jurisdiction.[3]

What does a conventional session feel like? Patients generally remain awake. The coil can produce clicking or tapping sounds and a tapping or pulsing sensation on the scalp. Headache, scalp discomfort or lightheadedness can occur, and treatment normally does not require general anaesthesia.[3][7][8]

What is ExoTMS? ExoTMS is BTL's proprietary implementation of transcranial magnetic stimulation. BTL describes EXOMIND as using patented ExoTMS technology built on the foundation of TMS. In practical terms, it belongs within the broader TMS category rather than representing a separate physical principle.[1][2]

What is EXOMIND? EXOMIND is the BTL system that delivers ExoTMS. The current Malaysian Medical Device Register lists EXOMIND as a registered medical device under registration number GB6594125-201327, with registration shown from 15 April 2025 to 14 April 2030. The local intended-purpose information should be checked against the current device record and the exact treatment being proposed.[8]

Does ExoTMS use the same basic mechanism as TMS? Yes. Published ExoTMS research describes stimulation using the EXOMIND device and reports device-specific engineering features such as ramp-up shaped pulses, a dual-core coil and integrated air cooling. Those features describe how this particular system is engineered. They do not change the underlying fact that ExoTMS is based on TMS.[1][9]

Is EXOMIND a completely different treatment from TMS? No. At the fundamental technology level, EXOMIND is a TMS system. The meaningful differences are in the specific device and protocol: coil and hardware configuration, pulse delivery, stimulation parameters, treatment schedule and intended clinical use. Comparing 'EXOMIND versus TMS' is therefore similar to comparing one branded implementation with a whole technology class.[1][3][9]

Can all TMS machines deliver the same treatment? No. TMS protocols vary by target, frequency, intensity, pulse pattern, coil configuration and schedule. Theta-burst and accelerated protocols can shorten treatment time compared with some conventional courses. A patient's outcome therefore cannot be predicted from the word 'TMS' alone.[3][5][6]

How long is a conventional TMS session? NIMH states that a typical rTMS session can last approximately 3–40 minutes, depending on the protocol. Conventional depression rTMS courses commonly involve daily treatment sessions five days a week for four to six weeks, although accelerated and other schedules exist.[3][5][6]

How long is an EXOMIND session? BTL describes EXOMIND sessions as taking under 30 minutes. In the 2026 sham-controlled ExoTMS sleep study, each of six sessions lasted 24.5 minutes, with sessions spaced three to seven days apart. That was a study protocol, not a universal schedule for every EXOMIND indication.[1][9]

What does the treatment feel like? Both are non-invasive and performed while the patient is awake. Standard TMS can cause clicking or tapping sensations and scalp discomfort. In the 2026 ExoTMS sleep study, participants reported no pain on the study's numerical pain scale after the final session, but that finding came from one protocol and should not be treated as a guarantee for every patient.[7][9]

Is there downtime? TMS is generally delivered as an outpatient treatment without general anaesthesia. The practical burden is often the treatment schedule rather than surgical recovery. Individual post-treatment instructions may vary, particularly if a patient develops headache, dizziness or other symptoms.[3][7]

Who may be suitable for TMS? Suitability depends on the clinical indication, treatment history and safety screening. For depression, conventional rTMS is commonly considered after inadequate response or intolerance to antidepressant treatment. Exact eligibility depends on the device, jurisdiction and protocol.[3][5][11]

Who may be suitable for EXOMIND in Malaysia? The Malaysian Medical Device Register is the relevant local reference for the registered device and its intended purpose. The current record should be checked when deciding whether a proposed use matches the device's registered indication. Registration does not mean that EXOMIND is appropriate for every person seeking better focus, motivation, sleep, stress reduction or general 'brain optimisation'. Those uses require separate clinical and evidence assessment.[8]

How different are the treatment courses? For conventional depression rTMS, a common course is around 20–30 sessions over four to six weeks. Published ExoTMS studies have used shorter courses. The 2026 sleep study used six sessions, while registered ExoTMS studies include four- or six-session protocols. The difference affects treatment burden, but it does not by itself establish superior effectiveness.[5][9][12][13]

Is TMS generally considered safe? TMS has a generally favorable safety profile when appropriate screening and stimulation parameters are used. A systematic review and meta-analysis of 53 randomized sham-controlled trials involving 3,273 participants with depression found no significant increase in serious adverse events or dropout due to adverse events with active TMS compared with sham. Headache, discomfort and pain at the stimulation site were more common with active TMS but were generally mild and transient.[7]

What safety issues matter before EXOMIND? Because EXOMIND uses TMS, relevant screening includes neurological history, seizure risk and metallic or electronic implants. The exact contraindications and precautions should be checked against the current EXOMIND labeling and treatment protocol. The 2026 ExoTMS sleep study excluded participants with metallic or magnetically sensitive implants in or near the head and implanted medical devices such as pacemakers or drug pumps.[9][11]

Does a newer device mean it is safer? Not automatically. Safety depends on the device, stimulation parameters, patient selection, monitoring and evidence. A newer engineering design may aim to improve comfort or efficiency, but novelty is not itself a safety outcome.[1][7][9]

Which has the larger evidence base, TMS or EXOMIND? TMS clearly has the larger evidence base. It has been studied for decades across multiple devices, protocols and clinical indications. NIMH describes rTMS as an authorized brain-stimulation therapy for specific indications, while consensus literature supports its clinical use in depression.[3][14]

How much evidence exists specifically for ExoTMS? The ExoTMS evidence base is newer and smaller. A 2026 sham-controlled sleep study enrolled 43 adults, with 31 receiving active ExoTMS and 12 receiving sham stimulation. It reported improvement in subjective sleep quality after six sessions and described the treatment as well tolerated. The investigators characterized the study as a pilot and noted that it was not powered for formal between-group comparisons.[9]

Does that study prove that EXOMIND is better than conventional TMS? No. It compared an ExoTMS protocol with sham stimulation, not directly with another TMS device. It therefore provides evidence about that specific ExoTMS protocol versus sham, not proof of superiority over conventional TMS.[9]

What about sleep, stress and other newer uses? These applications should be treated as indication-specific and developing. A study can show that a protocol is worth investigating without establishing it as a routine treatment for every person with the same broad goal. The distinction between established use, emerging evidence and investigational use matters.[8][9][12][13]

The most useful comparison is not 'Which brand is better?' Ask what problem is being treated, which exact device and protocol are being proposed, what evidence exists for that use, and how response and safety will be monitored. These questions keep the discussion focused on clinical reasoning rather than technology branding.[3][8][14]

The short answer is simple: EXOMIND is not separate from TMS. It is a BTL system that delivers TMS using BTL's proprietary ExoTMS implementation. The fundamental mechanism is shared, while device design, pulse delivery, treatment schedules, clinical indications and evidence can differ.[1][3][8][9]

• TMS is the broad technology class; EXOMIND is a specific BTL TMS system.
• ExoTMS uses the same fundamental electromagnetic principle as TMS.
• Conventional depression rTMS often uses more sessions than the shorter ExoTMS protocols studied to date.
• Both approaches require appropriate clinical screening and should not be described as risk-free.
• TMS has the larger established evidence base; ExoTMS evidence is newer and should be interpreted indication by indication.